68Ga-FT-FAPI与68Ga-FAPI-04在胃肠道肿瘤患者中的头对头比较
前瞻性研究纳入19例经组织学确诊的胃肠道肿瘤患者,在3天内配对行68Ga-FT-FAPI与68Ga-FAPI-04 PET/CT,比较原发灶及转移灶的SUVmax、靶本比和滞留指数。68Ga-FT-FAPI的摄取和靶本比均高于68Ga-FAPI-04,且在淋巴结、肝、骨和腹膜转移灶中的滞留指数更高。作者认为68Ga-FT-FAPI可能成为胃肠道肿瘤诊治的有效BNCT制剂。
要点
- 68Ga-FT-FAPI的SUVmax高于68Ga-FAPI-04(13.3 vs 10.0,P<0.001)。
- 68Ga-FT-FAPI的靶本比优于68Ga-FAPI-04(13.8 vs 8.2,P<0.001)。
- 淋巴结、肝、骨和腹膜转移灶中68Ga-FT-FAPI的滞留指数均高于68Ga-FAPI-04。
核心结论
- 68Ga-FT-FAPI在病灶摄取和检出率方面优于68Ga-FAPI-04,尤其在识别淋巴结、骨、肝和腹膜转移方面。
- 作者认为68Ga-FT-FAPI可能成为用于胃肠道肿瘤诊断和治疗的有效BNCT制剂。
研究设计与样本
- 前瞻性研究,纳入2024年3月至2025年4月在西京医院经组织学确诊的胃肠道肿瘤患者。
- 所有患者均在3天内配对接受68Ga-FT-FAPI PET/CT和68Ga-FAPI-04 PET/CT扫描。
- 最终纳入19例胃肠道肿瘤患者(12例男性、7例女性),中位年龄61.3岁(范围40-75岁)。
- 分析原发肿瘤和转移灶在两种显像方式下的SUVmax、靶本比(TBR)和滞留指数(RI)。
主要发现
- 共识别186个病灶。
- 68Ga-FT-FAPI的摄取高于68Ga-FAPI-04(13.3 vs 10.0,P<0.001)。
- 68Ga-FT-FAPI的靶本比优于68Ga-FAPI-04(13.8 vs 8.2,P<0.001)。
- 淋巴结转移灶中68Ga-FT-FAPI的RI高于68Ga-FAPI-04(88.7% vs 76.2%,P=0.001,n=62)。
- 肝转移灶中68Ga-FT-FAPI的RI高于68Ga-FAPI-04(115.4% vs 101.5%,P=0.032,n=38);骨转移灶中为70.8% vs 57.0%(P=0.008,n=24);腹膜转移灶中为102.9% vs 87.0%(P=0.041,n=26)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: FT-FAPI (FT, fast treatment) is a new FAP inhibitor with the potential to be used as a drug in boron neutron capture therapy (BNCT). The aim of this prospective study was to compare the diagnostic performance of 68Ga-FT-FAPI and 68Ga-FAPI-04 in patients with gastrointestinal (GI) tumors. METHODS: The study enrolled patients with histologically confirmed GI tumors diagnosed between March 2024 to April 2025 in Xijing Hospital. All the patients underwent paired 68Ga-FT-FAPI PET/CT and 68Ga-FAPI-04 PET/CT scans within three days. The maximum standard uptake value (SUVmax), tumor-to-background ratio (TBR), and retention index (RI) of the primary tumor and metastatic lesions were analyzed for both imaging modalities. RESULTS: A total of 19 patients with GI tumors (12 males and 7 females) with a median age of 61.3 years (range, 40-75 years) were finally enrolled in this study. A total of 186 lesions were identified.68Ga-FT-FAPI identified all the tumors clearly with a higher uptake than 68Ga-FAPI-04 (13.3 vs. 10.0, P < 0.001), and better TBR (13.8 vs. 8.2, P < 0.001). In terms of retention, the RIs of 68Ga-FT-FAPI were significantly higher than those of 68Ga-FAPI-04 for detecting lymph node metastases (88.7% vs. 76.2%, P = 0.001, n = 62), liver metastases (115.4% vs. 101.5%, P = 0.032, n = 38), bone metastases (70.8% vs. 57.0%, P = 0.008, n = 24), and peritoneal metastases (102.9% vs. 87.0%, P = 0.041, n = 26). CONCLUSION: 68Ga-FT-FAPI had a superior performance than 68Ga-FAPI-04 for uptake in lesions and a higher detection rate, especially for identifying metastases in lymph nodes, bone, liver and peritoneum. 68Ga-FT-FAPI may therefore be an effective BNCT agent for diagnosis and treatment of GI tumors.
引用
- Ma W, Yang S, Ye J, et al. Head-to-head comparison of 68Ga-FT-FAPI with 68Ga-FAPI-04 in patients with gastrointestinal tumors. Eur J Nucl Med Mol Imaging. 2025. PMID: 40464804. doi:10.1007/s00259-025-07372-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。